Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Summary: Highlights in Ph- ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

OncoPharm

J. Bossaer

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

ASH 2024 Insights: COG AALL1731 - Blinatumomab Added to Chemo in New…

2024 ASH Annual Meeting Insights Hub

S. Gupta

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancemen…

City of Hope

A. Salhotra

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

2024 Review of Frontline Treatment in ALL

Louisville Hematology Highlights

N. Short

Axatilimab in cGVHD: Mechanism of Action and Comparison With Current…

Noah Merin